Mekonos closes US$4.6mil capital raise

  • Post category:Matū / Mekonos

Our portfolio company Mekonos has formally closed its US$4.6mil capital raise, led by Novartis with participation from a number of US institutional VC Funds as well as Matū Fund. The capital will allow Mekonos to accelerate the development of System-on-Chip ex vivo gene engineering, with a clear path to market.

Read more here: